



Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

September 7, 2021

GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.

Details on the H.C. Wainwright fireside chat presentation are as follows:

- Title:** *H.C. Wainwright 23rd Annual Global Investment Conference*
- Presenters:** *Vipin Garg, Ph.D., Chief Executive Officer*
Scott Harris, M.D., Chief Medical Officer
- Date/Time:** *Monday, September 13, 2021 (virtual pre-record available at 7 a.m. EST)*

A webcast link to the fireside chat presentation will be accessible on the [Events](#) section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcelI™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on [LinkedIn](#)

Follow @Altimmunelnc on [Twitter](#)

Investor & Media Contacts:

Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com



Source: Altimmune, Inc